Drug Profile
Alogabat - Genentech
Alternative Names: GABA-Aa5 PAM; RG-7816; RG7816 alogabat; RO-7017773Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pervasive child development disorders
Most Recent Events
- 21 Jun 2023 Roche plans regulatory filing for Pervasive child development disorders, in 2026+ (Roche pipeline, June 2023)
- 29 Nov 2022 Hoffmann-La Roche plans a phase II trial for Angelman syndrome (In children, In adolescents) in January 2023 (PO) (NCT05630066)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Pervasive-child-development-disorders(In volunteers) in USA (PO, Capsule)